The fact sheets are meant to help those already participating in or those considering the Merit-based Incentive Payment System.
Rising drug costs are forcing some physicians to take matters into their own hands.
For the second time, the US FDA is warning physicians and patients to be aware of an experimental procedure that is being promoted as a treatment in autonomic dysfunction.
The large number of recalls of medical devices has pointed to a need for more active monitoring of product performance from the standpoints of both safety and efficacy.
Patients with chronic migraine and comorbidities incur nearly 2 times the health care costs incurred by patients with migraine alone.
Patients were 10% to 30% less likely to acquire a multidrug-resistant organism or C difficile if enhanced disinfection strategies were used in hospitals.
Though many would support changes, only 15% want the law completely repealed.
Katherine A. Roberts, MD, FACE, ECNU, discusses her choice to opt out of Medicare and offers advice to physicians considering doing the same.
Excessive charges negatively impact patients who are privately and uninsured.
Lengthy drug approval processes dampen competition, helping drive drug prices sky-high.
Several strategies for clinical practice and research may reduce the cost of MS treatment while maintaining efficacy.
Millions still struggle with the cost of prescription drugs.
Current government regulations allow drug manufacturers to charge monopolistic prices that aren't opposed by competing market forces.
HIPAA doesn't require providers to encrypt devices or electronic information, but one could say it is strongly encouraged.
Incentive payments to primary care physicians for providing comprehensive care to medically complex patients did not improve quality of care.
Fragmented care led to an additional $567 million to $1.1 billion in health care spending.
Substantial improvements have been proposed for care coordination, planning, primary care, and mental health.
The authors suggest that it's "perhaps not a fair direct comparison" to note that the CDC&P estimate of community prevalence for ASD is 15 per 1000 children.
Still, use of the method is still rare.
Nearly 25% of respondents taking DMDs use free or discounted drug programs.
Those who receive subsidies will likely not feel the effects of the rate hike.
The registry is a centralized data collection system that analyzes data on quality of care and patient outcomes.
Brand-name drug overuse accounted for 14% of these costs.
Most insurers' public exchange businesses are still not profitable.
Doctors trained on EHRs may be less compassionate towards patients, the author fears.
Some physicians are getting involved with their specialty societies to help develop new payment models.
The exorbitant cost of MS drugs consistently push the neurology specialty to the top of Medicare's list.
Hundreds of neurologists advocate for Congress to support the Telestroke FAST Act and the BRAIN Initiative.
EHRs need to have more usability, interoperability, physicians told AMA representatives at a town hall meeting.
Seven payment models that address 3 physician needs have been described by the AMA.
Neurology Advisor Articles
- Vitamin D Deficiency Affects Cognition in Multiple Sclerosis
- Hypothalamus May Play a Central Role in Chronic Migraine
- An Interdisciplinary Approach to Advanced Parkinson's Care
- Migraine Attacks Associated With Reduced Dopamine Levels
- Polypharmacy in Schizophrenia May Have Adverse Effect on Cognition
- Alzheimer's Mortality Increasing, But So Is At-Home Care
- Special Diets, Supplements for Autism Not Backed by Solid Evidence
- In MS, Disease Duration, Lesion Load Predict Relapses and Disability Progression
- Ocrelizumab May Improve Cognitive Function in Relapsing Multiple Sclerosis
- Teriflunomide for MS Associated With Low Rates of Infection, Lymphopenia